Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Chromagen/3M

This article was originally published in The Gray Sheet

Executive Summary

Chromagen/3M: Ink a collaborative development plan for novel solid phase extraction (SPE) technology to be used in Chromagen's diagnostic test products. SPE is one of three core technologies that San Diego, California-based Chromagen, a manufacturer of both nucleic-acid probe and immunoassay applications, has integrated into its Impact quantitative diagnostic assay technology. The development plan formalizes an informal arrangement between the two firms. Chromagen cites several performance advantages of the Impact platform technology in comparison to other diagnostic and therapeutic tools. For example, Impact offers sensitivity approaching that of PCR, greater specificity, reduction in time-to-result, and improved reproducibility, the company claims. Company officials say that clinical trials, slated to begin during the second quarter of 1996, will employ a microtiter plate format immunoassay and could test for diseases such as Chlamydia, Cryptosporidium, and Mychrobacterium tuberculosis...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT004712

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel